Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epoprostenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | PPARD | Q03181 | 2/20 | 0.71 |
| ▸ | PPARA | Q07869 | 2/20 | 0.71 |
| ▸ | PPARG | P37231 | 1/20 | 0.71 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.56 |
| ▸ | PTGFR | P43088 | 2/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.56 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epoprostenol SCHEMBL551616 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL16783375 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL16783374 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL22607961 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24340812 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL705594 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24033081 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL4165739 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL24612535 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA | |
| Epoprostenol SCHEMBL21283002 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515728-A2 | USE OF ORALLY-AVAILABLE PROSTACYCLIN DERIVATIVES FOR THE PRODUCTION OF A MEDICAMENT FOR THE TREATMENT OF DISEASE STATES ASSOCIATED WITH BONE MARROW OEDEMA | Schering Aktiengesellschaft (DE) | 2005-03-23 | — | — | EP | claimed |
| WO-2003103681-A2 | USE OF ORALLY-AVAILABLE PROSTACYCLIN DERIVATIVES FOR THE PRODUCTION OF A MEDICAMENT FOR THE TREATMENT OF DISEASE STATES ASSOCIATED WITH BONE MARROW OEDEMA | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-12-18 | — | — | WO | claimed |